Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ANAPC15_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ANAPC15_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ANAPC15_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ANAPC15_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ANAPC15_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00330451 | Oral cavity | OSCC | regulation of sister chromatid segregation | 47/7305 | 72/18723 | 5.69e-06 | 6.33e-05 | 47 |
GO:19058181 | Oral cavity | OSCC | regulation of chromosome separation | 47/7305 | 72/18723 | 5.69e-06 | 6.33e-05 | 47 |
GO:00109651 | Oral cavity | OSCC | regulation of mitotic sister chromatid separation | 43/7305 | 65/18723 | 8.50e-06 | 9.06e-05 | 43 |
GO:00300711 | Oral cavity | OSCC | regulation of mitotic metaphase/anaphase transition | 40/7305 | 60/18723 | 1.32e-05 | 1.33e-04 | 40 |
GO:00447841 | Oral cavity | OSCC | metaphase/anaphase transition of cell cycle | 42/7305 | 65/18723 | 2.57e-05 | 2.39e-04 | 42 |
GO:0051783 | Oral cavity | OSCC | regulation of nuclear division | 78/7305 | 139/18723 | 3.13e-05 | 2.86e-04 | 78 |
GO:20012512 | Oral cavity | OSCC | negative regulation of chromosome organization | 52/7305 | 86/18723 | 4.50e-05 | 3.84e-04 | 52 |
GO:19020991 | Oral cavity | OSCC | regulation of metaphase/anaphase transition of cell cycle | 40/7305 | 63/18723 | 7.19e-05 | 5.67e-04 | 40 |
GO:00458392 | Oral cavity | OSCC | negative regulation of mitotic nuclear division | 32/7305 | 48/18723 | 9.60e-05 | 7.25e-04 | 32 |
GO:00517842 | Oral cavity | OSCC | negative regulation of nuclear division | 34/7305 | 56/18723 | 8.17e-04 | 4.35e-03 | 34 |
GO:00330471 | Oral cavity | OSCC | regulation of mitotic sister chromatid segregation | 29/7305 | 46/18723 | 8.26e-04 | 4.38e-03 | 29 |
GO:00513041 | Oral cavity | OSCC | chromosome separation | 53/7305 | 96/18723 | 9.24e-04 | 4.86e-03 | 53 |
GO:00070941 | Oral cavity | OSCC | mitotic spindle assembly checkpoint | 24/7305 | 38/18723 | 2.21e-03 | 1.00e-02 | 24 |
GO:00711731 | Oral cavity | OSCC | spindle assembly checkpoint | 24/7305 | 38/18723 | 2.21e-03 | 1.00e-02 | 24 |
GO:00711741 | Oral cavity | OSCC | mitotic spindle checkpoint | 24/7305 | 38/18723 | 2.21e-03 | 1.00e-02 | 24 |
GO:00458411 | Oral cavity | OSCC | negative regulation of mitotic metaphase/anaphase transition | 25/7305 | 40/18723 | 2.22e-03 | 1.00e-02 | 25 |
GO:00330461 | Oral cavity | OSCC | negative regulation of sister chromatid segregation | 26/7305 | 43/18723 | 3.55e-03 | 1.49e-02 | 26 |
GO:00330481 | Oral cavity | OSCC | negative regulation of mitotic sister chromatid segregation | 26/7305 | 43/18723 | 3.55e-03 | 1.49e-02 | 26 |
GO:20008161 | Oral cavity | OSCC | negative regulation of mitotic sister chromatid separation | 26/7305 | 43/18723 | 3.55e-03 | 1.49e-02 | 26 |
GO:00315771 | Oral cavity | OSCC | spindle checkpoint | 24/7305 | 39/18723 | 3.64e-03 | 1.51e-02 | 24 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa0516639 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
hsa041109 | Esophagus | HGIN | Cell cycle | 38/1383 | 157/8465 | 6.70e-03 | 4.37e-02 | 3.47e-02 | 38 |
hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa05166114 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
hsa0411016 | Esophagus | HGIN | Cell cycle | 38/1383 | 157/8465 | 6.70e-03 | 4.37e-02 | 3.47e-02 | 38 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa041146 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0411411 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
hsa0412021 | Liver | Cirrhotic | Ubiquitin mediated proteolysis | 72/2530 | 142/8465 | 1.32e-07 | 1.97e-06 | 1.21e-06 | 72 |
hsa0516614 | Liver | Cirrhotic | Human T-cell leukemia virus 1 infection | 87/2530 | 222/8465 | 1.69e-03 | 8.01e-03 | 4.94e-03 | 87 |
hsa041104 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
hsa0412031 | Liver | Cirrhotic | Ubiquitin mediated proteolysis | 72/2530 | 142/8465 | 1.32e-07 | 1.97e-06 | 1.21e-06 | 72 |
hsa0516615 | Liver | Cirrhotic | Human T-cell leukemia virus 1 infection | 87/2530 | 222/8465 | 1.69e-03 | 8.01e-03 | 4.94e-03 | 87 |
hsa0411011 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANAPC15 | insertion | Nonsense_Mutation | novel | c.15_16insTATTAATTGAGGATCTAGCAGATGAT | p.Pro6TyrfsTer2 | p.P6Yfs*2 | | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANAPC15 | SNV | Missense_Mutation | rs767356574 | c.133N>A | p.Ala45Thr | p.A45T | | protein_coding | tolerated_low_confidence(0.09) | benign(0.339) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ANAPC15 | SNV | Missense_Mutation | novel | c.495N>A | p.Phe165Leu | p.F165L | | protein_coding | | benign(0.005) | TCGA-C5-A7XC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ANAPC15 | SNV | Missense_Mutation | novel | c.14T>G | p.Phe5Cys | p.F5C | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.993) | TCGA-EK-A2PL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
ANAPC15 | SNV | Missense_Mutation | novel | c.457N>T | p.Pro153Ser | p.P153S | | protein_coding | deleterious_low_confidence(0) | benign(0.003) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANAPC15 | SNV | Missense_Mutation | novel | c.13N>C | p.Phe5Leu | p.F5L | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.953) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC15 | SNV | Missense_Mutation | novel | c.268G>A | p.Asp90Asn | p.D90N | | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.99) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ANAPC15 | SNV | Missense_Mutation | novel | c.138G>T | p.Glu46Asp | p.E46D | | protein_coding | deleterious_low_confidence(0.04) | benign(0.201) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ANAPC15 | SNV | Missense_Mutation | novel | c.40N>A | p.Glu14Lys | p.E14K | | protein_coding | deleterious_low_confidence(0.05) | benign(0.133) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC15 | SNV | Missense_Mutation | rs767356574 | c.133N>A | p.Ala45Thr | p.A45T | | protein_coding | tolerated_low_confidence(0.09) | benign(0.339) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |